Clinical Trial: A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06969430) titled 'A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)' on May 05.

Brief Summary: The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization).

The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia

Intervention: DRUG: Debio 1562M

Administered as intravenous (IV) infusion

Recruitment Status: NOT_YET_RECRU...